204 related articles for article (PubMed ID: 35334240)
1. Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction.
Wang C; Xu Y; Lin Y; Zhou Y; Mao F; Zhang X; Shen S; Zhang Y; Sun Q
Breast; 2022 Jun; 63():61-70. PubMed ID: 35334240
[TBL] [Abstract][Full Text] [Related]
2. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
[TBL] [Abstract][Full Text] [Related]
3. Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value.
Wang C; Chen C; Lin Y; Zhou Y; Mao F; Zhu H; Zhang X; Shen S; Huang X; Wang X; Zhao B; Yang J; Sun Q
Sci Rep; 2020 Mar; 10(1):4660. PubMed ID: 32170181
[TBL] [Abstract][Full Text] [Related]
4. The Added Prognostic Value of Oncotype Recurrence Score to AJCC Prognostic Staging System in Stage III ER+/HER2- Breast Cancer.
Wang M; Zhang M; Chen H
Adv Ther; 2023 Sep; 40(9):3912-3925. PubMed ID: 37382865
[TBL] [Abstract][Full Text] [Related]
5. Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer.
Yoo SH; Kim TY; Kim M; Lee KH; Lee E; Lee HB; Moon HG; Han W; Noh DY; Han SW; Kim TY; Im SA
Clin Breast Cancer; 2020 Apr; 20(2):98-107.e1. PubMed ID: 31522959
[TBL] [Abstract][Full Text] [Related]
6. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
[TBL] [Abstract][Full Text] [Related]
7. Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis.
Marazzi F; Barone R; Masiello V; Magri V; Mulè A; Santoro A; Cacciatori F; Boldrini L; Franceschini G; Moschella F; Naso G; Tomao S; Gambacorta MA; Mantini G; Masetti R; Smaniotto D; Valentini V
Clin Breast Cancer; 2020 Oct; 20(5):e600-e611. PubMed ID: 32565110
[TBL] [Abstract][Full Text] [Related]
8. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Dowsett M; Sestak I; Regan MM; Dodson A; Viale G; Thürlimann B; Colleoni M; Cuzick J
J Clin Oncol; 2018 Jul; 36(19):1941-1948. PubMed ID: 29676944
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
10. A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age.
Yu J; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
J Transl Med; 2021 Feb; 19(1):75. PubMed ID: 33593381
[TBL] [Abstract][Full Text] [Related]
11. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC; Miller DP; Shak S; Petkov VI
Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
[TBL] [Abstract][Full Text] [Related]
13. Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
Richman J; Ring A; Dowsett M; Sestak I
Breast Cancer Res Treat; 2021 Feb; 186(1):115-123. PubMed ID: 33222093
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of nomograms to predict survival in patients with invasive micropapillary carcinoma of the breast.
Cheng Y; Zhang P; Huang Y; Zhang Z; Tang R; Chi F; Sun JY; He Z
BMJ Open; 2023 Feb; 13(2):e065312. PubMed ID: 36810178
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Clinical Treatment Score Post-Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea.
Lee JH; Lee SK; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
Front Oncol; 2021; 11():691277. PubMed ID: 34239805
[TBL] [Abstract][Full Text] [Related]
16. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
[TBL] [Abstract][Full Text] [Related]
17. Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients.
Pan B; Xu Y; Yao R; Cao X; Zhou X; Hao Z; Zhang Y; Wang C; Shen S; Luo Y; Zhu Q; Ren X; Kong L; Zhou Y; Sun Q
J Transl Med; 2023 Nov; 21(1):798. PubMed ID: 37946210
[TBL] [Abstract][Full Text] [Related]
18. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Orucevic A; Bell JL; McNabb AP; Heidel RE
Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
[TBL] [Abstract][Full Text] [Related]
19. Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
Noordhoek I; Blok EJ; Meershoek-Klein Kranenbarg E; Putter H; Duijm-de Carpentier M; Rutgers EJT; Seynaeve C; Bartlett JMS; Vannetzel JM; Rea DW; Hasenburg A; Paridaens R; Markopoulos CJ; Hozumi Y; Portielje JEA; Kroep JR; van de Velde CJH; Liefers GJ
J Clin Oncol; 2020 Oct; 38(28):3273-3281. PubMed ID: 32706636
[TBL] [Abstract][Full Text] [Related]
20. Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis.
Shrestha A; Cullinane C; Evoy D; Geraghty J; Rothwell J; Walshe J; McCartan D; McDermott E; Prichard R
Br J Surg; 2022 Apr; 109(5):411-417. PubMed ID: 35194632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
